Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether the company will face a downgrade to high yield or whether it can find the “transformative deal” needed for a core generics comeback. Next year looks possible for recovery, but what of Teva’s long-term revival?
Story Continues
